+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report by Technology, End-use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 120 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921077
Description Jump to:
The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

Breast Cancer Core Needle Biopsy Market Report Highlights

  • By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.
  • By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.
  • North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Technology Segment
1.1.1.2. End Use
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objective
1.4.1. Objective 1
1.4.2. Objective 2
1.4.3. Objective 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information or Data Analysis:
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Trends and Outlook
3.4. Market Drivers
3.4.1. Growing prevalence of breast cancer
3.4.2. Advancement in imaging technologies and biopsy techniques
3.4.3. Rising inclination towards minimally invasive procedures
3.5. Market Restraint
3.5.1. High cost of core needle biopsy procedures
3.5.2. Limited expertise and training
3.6. Industry Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Technology Business Analysis
4.1. Breast Cancer Core Needle Biopsy Market: Technology Movement Analysis
4.2. MRI-Based Breast Biopsy
4.2.1. MRI-Based Breast Biopsy Market, 2018-2030 (USD Million)
4.3. Fermentation Ultrasound-Based Breast Biopsy
4.3.1. Ultrasound-Based Breast Biopsy Market, 2018-2030 (USD Million)
4.4. Mammography-Based (Stereotactic) Breast Biopsy
4.4.1. Mammography-Based (Stereotactic) Breast Biopsy Market, 2018-2030 (USD Million)
4.5. CT-Based Breast Biopsy
4.5.1. CT-Based Breast Biopsy Market, 2018-2030 (USD Million)
4.6. Other Image-Based Breast Biopsy
4.6.1. Other Image-Based Breast Biopsy Market, 2018-2030 (USD Million)
Chapter 5. End-use Business Analysis
5.1. Breast Cancer Core Needle Biopsy Market: End-use Movement Analysis
5.2. Hospitals & Diagnostic Laboratories
5.2.1. Hospitals & Diagnostic Laboratories Market, 2018-2030 (USD Million)
5.3. Pharmaceutical & Biotechnology companies
5.3.1. Pharmaceutical & Biotechnology Companies, Market, 2018-2030 (USD Million)
5.4. Academic & Research Institutes
5.4.1. Academic And Research Institutes Market, 2018-2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. Breast Cancer Core Needle Biopsy Market Share By Region, 2022 & 2030
6.2. North America
6.2.1. SWOT Analysis
6.2.2. North America Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.2.3. U.S.
6.2.3.1. Key Country Dynamics
6.2.3.2. Target Disease Prevalence
6.2.3.3. Competitive Scenario
6.2.3.4. Regulatory Framework
6.2.3.5. U.S. Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.2.4. Canada
6.2.4.1. Key Country Dynamics
6.2.4.2. Target Disease Prevalence
6.2.4.3. Competitive Scenario
6.2.4.4. Regulatory Framework
6.2.4.5. Canada Breast Cancer Core Needle Biopsy Market, 2018-2030 (USD Million)
6.3. Europe
6.3.1. SWOT Analysis
6.3.2. Europe Breast Cancer Core Needle Biopsy Market, 2018-2030 (USD Million)
6.3.3. UK
6.3.3.1. Key Country Dynamics
6.3.3.2. Target Disease Prevalence
6.3.3.3. Competitive Scenario
6.3.3.4. Regulatory Framework
6.3.3.5. UK Breast Cancer Core Needle Biopsy Market, 2018-2030 (USD Million)
6.3.4. Germany
6.3.4.1. Key Country Dynamics
6.3.4.2. Target Disease Prevalence
6.3.4.3. Competitive Scenario
6.3.4.4. Regulatory Framework
6.3.4.5. Germany Breast Cancer Core Needle Biopsy Market, 2018-2030 (USD Million)
6.3.5. France
6.3.5.1. Key Country Dynamics
6.3.5.2. Target Disease Prevalence
6.3.5.3. Competitive Scenario
6.3.5.4. Regulatory Framework
6.3.5.5. France Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.3.6. Italy
6.3.6.1. Key Country Dynamics
6.3.6.2. Target Disease Prevalence
6.3.6.3. Competitive Scenario
6.3.6.4. Regulatory Framework
6.3.6.5. Italy Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.3.7. Spain
6.3.7.1. Key Country Dynamics
6.3.7.2. Target Disease Prevalence
6.3.7.3. Competitive Scenario
6.3.7.4. Regulatory Framework
6.3.7.5. Spain Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.3.8. Denmark
6.3.8.1. Key Country Dynamics
6.3.8.2. Target Disease Prevalence
6.3.8.3. Competitive Scenario
6.3.8.4. Regulatory Framework
6.3.8.5. Denmark Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.3.9. Sweden
6.3.9.1. Key Country Dynamics
6.3.9.2. Target Disease Prevalence
6.3.9.3. Competitive Scenario
6.3.9.4. Regulatory Framework
6.3.9.5. Sweden Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.3.10. Norway
6.3.10.1. Key Country Dynamics
6.3.10.2. Target Disease Prevalence
6.3.10.3. Competitive Scenario
6.3.10.4. Regulatory Framework
6.3.10.5. Norway Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4. Asia-Pacific
6.4.1. SWOT Analysis
6.4.2. Asia-Pacific Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.3. Japan
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Competitive Scenario
6.4.3.4. Regulatory Framework
6.4.3.5. Japan Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.4. China
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Competitive Scenario
6.4.4.4. Regulatory Framework
6.4.4.5. China Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.5. India
6.4.5.1. Key Country Dynamics
6.4.5.2. Target Disease Prevalence
6.4.5.3. Competitive Scenario
6.4.5.4. Regulatory Framework
6.4.5.5. India Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.6. Australia
6.4.6.1. Key Country Dynamics
6.4.6.2. Target Disease Prevalence
6.4.6.3. Competitive Scenario
6.4.6.4. Regulatory Framework
6.4.6.5. Australia Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.7. Thailand
6.4.7.1. Key Country Dynamics
6.4.7.2. Target Disease Prevalence
6.4.7.3. Competitive Scenario
6.4.7.4. Regulatory Framework
6.4.7.5. Thailand Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.4.8. South Korea
6.4.8.1. Key Country Dynamics
6.4.8.2. Target Disease Prevalence
6.4.8.3. Competitive Scenario
6.4.8.4. Regulatory Framework
6.4.8.5. South Korea Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.5. Latin America
6.5.1. SWOT Analysis
6.5.2. Latin America Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.5.3. Brazil
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Competitive Scenario
6.5.3.4. Regulatory Framework
6.5.3.5. Brazil Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Competitive Scenario
6.5.4.4. Regulatory Framework
6.5.4.5. Mexico Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.5.5. Argentina
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Competitive Scenario
6.5.5.4. Regulatory Framework
6.5.5.5. Argentina Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.6. MEA
6.6.1. SWOT Analysis
6.6.2. MEA Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.6.3. South Africa
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Competitive Scenario
6.6.3.4. Regulatory Framework
6.6.3.5. South Africa Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.6.4. Saudi Arabia
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Competitive Scenario
6.6.4.4. Regulatory Framework
6.6.4.5. Saudi Arabia Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.6.5. UAE
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Competitive Scenario
6.6.5.4. Regulatory Framework
6.6.5.5. UAE Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
6.6.6. Kuwait
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Competitive Scenario
6.6.6.4. Regulatory Framework
6.6.6.5. Kuwait Breast Cancer Core Needle Biopsy, 2018-2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Share Analysis, 2022
7.4. Company Profiles/Listing
7.4.1. Intact Medical Corporation.
7.4.1.1. Overview
7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Ethicon Surgical Technologies
7.4.2.1. Overview
7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Gallini SRL
7.4.3.1. Overview
7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Leica Biosystems Nussloch GmbH
7.4.4.1. Overview
7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Hologic, Inc.
7.4.5.1. Overview
7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Argon Medical Devices
7.4.6.1. Overview
7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Encapsule Medical Devices LLC
7.4.7.1. Overview
7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Cook Medical Incorporated
7.4.8.1. Overview
7.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Becton, Dickinson and Company
7.4.9.1. Overview
7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. C.R. Bard, Inc.
7.4.10.1. Overview
7.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global breast cancer core needle biopsy market, by technology, 2018-2030 (USD Million)
Table 3 Global breast cancer core needle biopsy market, by end-use, 2018-2030 (USD Million)
Table 4 Global breast cancer core needle biopsy market, by region, 2018-2030 (USD Million)
Table 5 North America breast cancer core needle biopsy market, by country, 2018-2030 (USD Million)
Table 6 North America breast cancer core needle biopsy market, by technology, 2018-2030 (USD Million)
Table 7 North America breast cancer core needle biopsy market, by end-use, 2018-2030 (USD Million)
Table 8 U.S. breast cancer core needle biopsy market, by technology, 2018-2030 (USD Million)
Table 9 U.S. breast cancer core needle biopsy market, by end-use, 2018-2030 (USD Million)
Table 10 Canada breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 11 Canada breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 12 Europe breast cancer core needle biopsy, by country, 2018-2030 (USD Million)
Table 13 Europe breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 14 Europe breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 15 UK breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 16 UK breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 17 Germany breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 18 Germany breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 19 France breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 20 France breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 21 Italy breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 22 Italy breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 23 Spain breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 24 Spain breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 25 Denmark breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 26 Denmark breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 27 Sweden breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 28 Sweden breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 29 Norway breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 30 Norway breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 31 Asia-Pacific breast cancer core needle biopsy, by country, 2018-2030 (USD Million)
Table 32 Asia-Pacific breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 33 Asia-Pacific breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 34 Japan breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 35 Japan breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 36 China breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 37 China breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 38 India breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 39 India breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 40 Australia breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 41 Australia breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 42 Thailand breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 43 Thailand breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 44 South Korea breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 45 South Korea breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 46 Latin America breast cancer core needle biopsy, by country, 2018-2030 (USD Million)
Table 47 Latin America breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 48 Latin America breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 49 Brazil breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 50 Brazil breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 51 Mexico breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 52 Mexico breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 53 Argentina breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 54 Argentina breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 55 Middle East & Africa breast cancer core needle biopsy, by country, 2018-2030 (USD Million)
Table 56 Middle East & Africa breast cancer core needle biopsy, by technology, 2018-2030, (USD
Table 57 Middle East & Africa breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 58 South Africa breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 59 South Africa breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 60 Saudi Arabia breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 61 Saudi Arabia breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 62 UAE breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 63 UAE breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
Table 64 Kuwait breast cancer core needle biopsy, by technology, 2018-2030 (USD Million)
Table 65 Kuwait breast cancer core needle biopsy, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 breast cancer core needle biopsy market segmentation
Figure 8 Market snapshot, 2022
Figure 9 Market trends & outlook
Figure 10 Market driver relevance analysis (current & future impact)
Figure 11 Market restraint relevance analysis (current & future impact)
Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
Figure 13 Porter’s Five Forces analysis
Figure 14 Market penetration & growth prospect mapping, 2022
Figure 15 Global breast cancer core needle biopsy market: Technology movement analysis
Figure 16 Global breast cancer core needle biopsy market, for MRI-based breast biopsy, 2018-2030 (USD Million)
Figure 17 Global breast cancer core needle biopsy market, for ultrasound-based breast biopsy, 2018-2030 (USD Million)
Figure 18 Global breast cancer core needle biopsy market, for mammography-based (stereotactic) breast biopsy, 2018-2030 (USD Million)
Figure 19 Global breast cancer core needle biopsy market, for CT-based breast biopsy, 2018-2030 (USD Million)
Figure 20 Global breast cancer core needle biopsy market, for other image-based breast biopsy, 2018-2030 (USD Million)
Figure 21 Global breast cancer core needle biopsy market: End use movement analysis
Figure 22 Global breast cancer core needle biopsy market, for hospitals & diagnostic laboratories, 2018-2030 (USD Million)
Figure 23 Global breast cancer core needle biopsy market, for pharmaceutical & biotechnology companies, 2018-2030 (USD Million)
Figure 24 Global breast cancer core needle biopsy market, for academic & research institutes, 2018-2030 (USD Million)
Figure 25 Regional marketplace: Key takeaways
Figure 26 Regional outlook, 2022 & 2030
Figure 27 Global breast cancer core needle biopsy market: Region movement analysis
Figure 28 North America breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 29 U.S. breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 30 Canada breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 31 Europe breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 32 Germany breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 33 UK breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 34 France breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 35 Italy breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 36 Spain breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 37 Denmark breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 38 Sweden breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 39 Norway breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 40 Asia-Pacific breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 41 Japan breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 42 China breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 43 India breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 44 Australia breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 45 South Korea breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 46 Thailand breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 47 Latin America breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 48 Brazil breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 49 Mexico breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 50 Argentina breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 51 Middle East and Africa breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 52 South Africa breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 53 Saudi Arabia breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 54 UAE breast cancer core needle biopsy market, 2018-2030 (USD Million)
Figure 55 Kuwait breast cancer core needle biopsy market, 2018-2030 (USD Million)

Companies Mentioned

  • Intact Medical Corporation.
  • Ethicon Surgical Technologies
  • Gallini SRL
  • Leica Biosystems Nussloch GmbH
  • Hologic, Inc.
  • Argon Medical Devices
  • Encapsule Medical Devices LLC
  • Cook Medical Incorporated
  • Becton, Dickinson and Company
  • C.R. Bard, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages120
PublishedDecember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 776.97 Million
Forecasted Market Value ( USD ) by 2030 $ 1150 Million
Compound Annual Growth Rate4.9%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Breast Biopsy Market by Product (Assay Kits, Biopsy Needles, Biopsy Tables), Type (Liquid Breast Biopsy, Needle Breast Biopsy, Open Surgical Breast Biopsy), Guidance, Application - Forecast 2024-2030 - Product Image

Global Breast Biopsy Market by Product (Assay Kits, Biopsy Needles, Biopsy Tables), Type (Liquid Breast Biopsy, Needle Breast Biopsy, Open Surgical Breast Biopsy), Guidance, Application - Forecast 2024-2030

  • Report
  • 191 Pages
  • Global
From
Global Breast Biopsy Market (Core Needle, Vacuum Assisted & Fine Needle Aspiration): Insights & Forecast with Potential Impact of COVID-19 (2023-2027) - Product Image

Global Breast Biopsy Market (Core Needle, Vacuum Assisted & Fine Needle Aspiration): Insights & Forecast with Potential Impact of COVID-19 (2023-2027)

  • Report
  • 71 Pages
  • Global
From
Breast Cancer Core Needle Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Breast Cancer Core Needle Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 181 Pages
  • Global
From
Breast Biopsy Devices Market by Type (Needles, Tables, Assay Kits, Liquid Biopsy), Procedure (CNB, FNAB, VAB, Surgical), Technique (Stereotactic, USG, MRI), Application (Screening, Treatment), End User (Hospitals, Clinic) & Region - Global Forecast to 2028 - Product Image

Breast Biopsy Devices Market by Type (Needles, Tables, Assay Kits, Liquid Biopsy), Procedure (CNB, FNAB, VAB, Surgical), Technique (Stereotactic, USG, MRI), Application (Screening, Treatment), End User (Hospitals, Clinic) & Region - Global Forecast to 2028

  • Report
  • 260 Pages
  • Global
From
Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Core Needle Biopsy), By Application (Breast Cancer, Lung Cancer), By Product (Kits & Consumables, Instruments), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 140 Pages
  • Global
From

About the Breast Cancer Core Needle Biopsy Market

In the Women's Health sector, the Breast Cancer Core Needle Biopsy market encompasses products and procedures utilized for the diagnostic sampling of breast tissue. Core needle biopsy (CNB) is a minimally invasive method for obtaining breast tissue samples for histopathological examination, vital for the accurate diagnosis and staging of breast cancer. The market is driven by technological advancements in biopsy devices, increasing awareness of breast cancer screening, and the rising prevalence of breast cancer worldwide. These devices are designed to extract a small cylinder of tissue with minimal discomfort and scarring. The market reflects an integration of innovations such as image-guided biopsy systems, including ultrasound, stereotactic, and MRI-guided procedures, which improve the precision of tissue sampling. Companies that play a notable role in the Breast Cancer Core Needle Biopsy market include Hologic, Inc., which provides a range of mammography and biopsy solutions; Becton, Dickinson and Company (BD), known for medical technology including biopsy instruments; Devicor Medical Products, Inc., a part of Leica Biosystems, specializing in vacuum-assisted breast biopsy systems; Cook Medical, which develops medical devices used in minimally invasive procedures; and Argon Medical Devices, Inc., which produces products used in various biopsy procedures. These companies are at the forefront of innovation and supply within the field and contribute substantially to advancements in Women's Health diagnostics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.